The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

Harmony's Martinsburg clinic now offers SPRAVATO®, an FDA-approved nasal spray for treatment-resistant depression, providing fast-acting symptom relief. MARTINSBURG, WV, UNITED STATES ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Yesterday, the FDA expanded approval for Spravato, a ketamine-derived nasal spray, to be used as a standalone treatment for severe depression. This decision marks a significant milestone ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

Spravato has been approved since 2019 for TRD ... Despite J&J's high hopes for the drug, sales have remained low, not warranting a mention in any of J&J's quarterly financial updates since ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...